Compare · HUMA vs SGEN
HUMA vs SGEN
Side-by-side comparison of Humacyte Inc. (HUMA) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUMA and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN is the larger of the two at $23.34B, about 76.2x HUMA ($306.4M).
- HUMA has hit the wire 7 times in the past 4 weeks while SGEN has been quiet.
- SGEN has more recent analyst coverage (25 ratings vs 11 for HUMA).
- Company
- Humacyte Inc.
- Seagen Inc.
- Price
- $1.38+1.85%
- $228.86-0.01%
- Market cap
- $306.4M
- $23.34B
- 1M return
- +27.31%
- -
- 1Y return
- -46.39%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2001
- News (4w)
- 7
- 0
- Recent ratings
- 11
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest HUMA
- Humacyte Inc. filed SEC Form 8-K: Other Events
- Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Director Sebelius Kathleen bought $50,000 worth of shares (56,818 units at $0.88), increasing direct ownership by 62% to 148,025 units (SEC Form 4)
- Director Constantino Michael T. bought $9,840 worth of shares (11,000 units at $0.89), increasing direct ownership by 33% to 43,950 units (SEC Form 4)
- CFO and Chief Corp. Dev. Off Sander Dale A. sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 267,213 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Parikh Shamik J sold $41,147 worth of shares (45,887 units at $0.90) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 272,713 units (SEC Form 4) (for withholding tax)
- Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- SEC Form S-8 filed by Humacyte Inc.
- SEC Form 10-Q filed by Humacyte Inc.
- Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)